ArticleFrontiers in medicine2026
SCORE2 cardiovascular risk score for cognitive impairment in women aged 40 years and above: a pragmatic triage signal in primary care - a single-center family medicine feasibility study with machine learning support.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Screening-defined cognitive impairment (CI; MMSE ≤23) in midlife women is under-recognized in primary care. SCORE2 is a 10-year cardiovascular disease risk score already routinely calculated in many primary-care settings. We evaluated whether SCORE2 provides a clinically useful triage signal for CI; secondarily, a parsimonious machine learning (ML) model was developed from routinely-collected data to support the SCORE2 signal. Methods: In this single-center, cross-sectional feasibility study, 89 women aged 40-68 years (52 hypertensive, 37 normotensive controls) were analyzed. CI was defined as a Mini-Mental State Examination (MMSE) total score ≤23 (validated Turkish cut-off). The association between SCORE2 (high-risk-region coefficients) and CI was assessed by χ Results: SCORE2 showed a clear dose-response association with CI: prevalence rose from 21.2% (Low) to 50.0% (Moderate), 62.5% (High), and 60.0% (Very High) (χ Conclusion: SCORE2 - already routinely calculated in primary care - provides a clinically useful triage signal for cognitive impairment at no additional resource cost; women at high cardiovascular risk may benefit from formal cognitive testing. The parsimonious ML model mechanistically supports the SCORE2 signal. As a single-center feasibility study, multi-center prospective external validation is required before clinical deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.